Free Trial
NASDAQ:FBLG

FibroBiologics Q4 2024 Earnings Report

FibroBiologics logo
$0.96 -0.02 (-2.34%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$0.96 +0.00 (+0.30%)
As of 08:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroBiologics EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.10
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 31, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

FibroBiologics' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Remove Ads

FibroBiologics Earnings Headlines

The Crypto Market is About to Change Lives
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free.
FibroBiologics announces opening of new lab facility
Zacks Small Cap Comments on FibroBiologics Q1 Earnings
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG) operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile

More Earnings Resources from MarketBeat